File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Elevated plasma transforming growth factor-β1 levels in breast cancer patients decrease after surgical removal of the tumor

TitleElevated plasma transforming growth factor-β1 levels in breast cancer patients decrease after surgical removal of the tumor
Authors
Issue Date1995
Citation
Annals of Surgery, 1995, v. 222, n. 2, p. 155-162 How to Cite?
AbstractObjective: The authors determined whether untreated breast cancer patients have elevated plasma levels of transforming growth factor-β1 (TGF-β1). Summary Background Data: Increased plasma TGF-β1 levels recently were found after chemotherapy in patients with advanced breast cancer. However, it currently is unknown whether this elevation in plasma TGF-β1 is caused by chemotherapy-induced normal tissue damage or whether it results from the presence of the tumor. Methods: An enzyme-linked immunosorbent assay was used to measure plasma TGF-β1 levels in 26 newly diagnosed breast cancer patients before and after definitive surgery. Patients were grouped by postoperative tumor status: 1) negative lymph nodes (group 1); 2) positive lymph nodes (group 2); and 3) overt residual disease (group 3). The site of TGF-β1 production in the tumors was localized by immunohistochemistry and in situ hybridization. Results: Plasma TGF-β1 levels were elevated preoperatively in 81% of the patients; TGF-β2 and TGF-β3 were undetectable. The preoperative TGF-β1 levels in the three patient groups were similar; however, the postoperative plasma TGF-β1 levels differed by disease status. The mean plasma TGF-β1 level in group 1 (n = 12) normalized after surgery (19.3 ± 3.2 vs. 5.5 ± 1.0 ng/mL, p < 0.081). In contrast, the mean plasma TGF-β1 levels remained above normal in both group 2 (n = 9) and group 3 (n = 5) after surgery. Transforming growth factor-β1 expression was found to be preferentially increased in the tumor stroma. Conclusions: Breast tumors result in increased plasma TGF-β1 levels in 81% of patients. After surgical removal of the primary tumor, the plasma TGF-β1 level normalizes in the majority of patients; persistently elevated levels correlate with the presence of lymph node metastases or overt residual tumor. These findings suggest that the usefulness of TGF-β1 as a potential plasma marker for breast tumors deserves further study.
Persistent Identifierhttp://hdl.handle.net/10722/266757
ISSN
2021 Impact Factor: 13.787
2020 SCImago Journal Rankings: 4.153
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorKong, F. M.-
dc.contributor.authorAnscher, M. S.-
dc.contributor.authorMurase, T.-
dc.contributor.authorAbbott, B. D.-
dc.contributor.authorIglehart, J. D.-
dc.contributor.authorJirtle, R. L.-
dc.date.accessioned2019-01-31T07:19:30Z-
dc.date.available2019-01-31T07:19:30Z-
dc.date.issued1995-
dc.identifier.citationAnnals of Surgery, 1995, v. 222, n. 2, p. 155-162-
dc.identifier.issn0003-4932-
dc.identifier.urihttp://hdl.handle.net/10722/266757-
dc.description.abstractObjective: The authors determined whether untreated breast cancer patients have elevated plasma levels of transforming growth factor-β1 (TGF-β1). Summary Background Data: Increased plasma TGF-β1 levels recently were found after chemotherapy in patients with advanced breast cancer. However, it currently is unknown whether this elevation in plasma TGF-β1 is caused by chemotherapy-induced normal tissue damage or whether it results from the presence of the tumor. Methods: An enzyme-linked immunosorbent assay was used to measure plasma TGF-β1 levels in 26 newly diagnosed breast cancer patients before and after definitive surgery. Patients were grouped by postoperative tumor status: 1) negative lymph nodes (group 1); 2) positive lymph nodes (group 2); and 3) overt residual disease (group 3). The site of TGF-β1 production in the tumors was localized by immunohistochemistry and in situ hybridization. Results: Plasma TGF-β1 levels were elevated preoperatively in 81% of the patients; TGF-β2 and TGF-β3 were undetectable. The preoperative TGF-β1 levels in the three patient groups were similar; however, the postoperative plasma TGF-β1 levels differed by disease status. The mean plasma TGF-β1 level in group 1 (n = 12) normalized after surgery (19.3 ± 3.2 vs. 5.5 ± 1.0 ng/mL, p < 0.081). In contrast, the mean plasma TGF-β1 levels remained above normal in both group 2 (n = 9) and group 3 (n = 5) after surgery. Transforming growth factor-β1 expression was found to be preferentially increased in the tumor stroma. Conclusions: Breast tumors result in increased plasma TGF-β1 levels in 81% of patients. After surgical removal of the primary tumor, the plasma TGF-β1 level normalizes in the majority of patients; persistently elevated levels correlate with the presence of lymph node metastases or overt residual tumor. These findings suggest that the usefulness of TGF-β1 as a potential plasma marker for breast tumors deserves further study.-
dc.languageeng-
dc.relation.ispartofAnnals of Surgery-
dc.titleElevated plasma transforming growth factor-β1 levels in breast cancer patients decrease after surgical removal of the tumor-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1097/00000658-199508000-00007-
dc.identifier.pmid7543740-
dc.identifier.scopuseid_2-s2.0-0029133133-
dc.identifier.volume222-
dc.identifier.issue2-
dc.identifier.spage155-
dc.identifier.epage162-
dc.identifier.isiWOS:A1995RM73400007-
dc.identifier.issnl0003-4932-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats